Introduction
============

Chronic obstructive pulmonary disease (COPD) is defined as a disease state characterized by poorly reversible airflow limitation and loss of pulmonary capillary bed. It is usually progressive and associated with abnormal inflammatory responses in the lung ([@b147-copd-1-381]). Chronic inflammation is a predominant feature of COPD and involves the airways ([@b179-copd-1-381]), lung parenchyma ([@b178-copd-1-381]), and pulmonary vasculature ([@b149-copd-1-381]). It is caused by exposure to inhaled noxious particles and gases present in tobacco smoke ([@b211-copd-1-381]; [@b181-copd-1-381]) and likely in other air pollutants that may be inhaled during breathing. Macrophages, T lymphocytes (predominately CD8+), and neutrophils are increased numerically as well as activated ([@b153-copd-1-381]), this results in the release of a variety of mediators ([@b84-copd-1-381]; [@b115-copd-1-381]; [@b215-copd-1-381]; [@b12-copd-1-381]) that are believed to be capable of unbalance the protease-antiprotease equilibrium ([@b58-copd-1-381]; [@b191-copd-1-381]) and damage lung structures ([@b99-copd-1-381]; [@b183-copd-1-381]).

The pathological hallmarks of COPD are inflammation of the peripheral airways and destruction of lung parenchyma or emphysema ([@b199-copd-1-381]). The functional consequence of these abnormalities is expiratory airflow limitation. Since the determinants of expiratory flow through the airways are both the driving alveolar pressure that promotes flow (elastic recoil of the lung) and the opposing resistance of the airways, the reduction in flow occurring in COPD is defined more accurately as airflow limitation rather than airflow obstruction, since both loss of elastic recoil and increase in airway resistance play an important role ([@b162-copd-1-381]). Emphysema will contribute to the airflow limitation by reducing the elastic recoil of the lung through parenchymal destruction, as well as by reducing the elastic load applied to the airways through destruction of alveolar attachments. On the other hand, inflammation of the peripheral airways will contribute to the airflow limitation by increasing the thickness of the airway wall which, together with fibrosis and smooth muscle hypertrophy, may cause airway narrowing ([@b200-copd-1-381]). The role of mucus hypersecretion in the development of chronic airflow limitation is still controversial ([@b154-copd-1-381]; [@b207-copd-1-381]).

Expiratory flow limitation and dynamic hyperinflation (DH) are clinical and pathologic concepts that have been present for well over 100 years. Recent developments have revitalized the interest on this crucial psychopathological consequence of obstructive disease. In accordance with this renewed interest, a provocative hypothesis has been put forward recently that proposes that the transition from peripheral airways disease to COPD follows three pathophysiological stages defined by the severity of expiratory flow limitation: In Stage I, closing volume eventually exceeds the functional residual capacity (FRC); in Stage II tidal volume expiratory flow limitation (EFL) develops; and in Stage III, DH increases to a point that produces dyspnea and exercise limitation. The presence of airway closure (Stage I) and EFL (Stage II) may promote peripheral airway injury and accelerate the abnormalities of lung function ([@b111-copd-1-381]).

Pathophysiology of dynamic hyperinflation
=========================================

Nonmuscular factors
-------------------

The respiratory system (ie, the combined elastic recoil of the lung and chest wall) is an elastic structure able to change its shape and volume in order to breathe the necessary air in, and the alveolar gas out, to sustain the amount of gas exchange needed to match metabolic needs. Under normal physiological conditions the respiratory muscles provide the power to produce such changes in volume. For a given change in pleural pressure generated by the respiratory muscles, the attainable end-inspiratory and end-expiratory volumes are determined by the passive pressure--volume (P--V) relationship of the respiratory system ([Figure 1](#f1-copd-1-381){ref-type="fig"}) ([@b110-copd-1-381]; [@b2-copd-1-381]). The P--V behavior of the respiratory system is distinctly sigmoid ([Figure 1](#f1-copd-1-381){ref-type="fig"}) since the respiratory system is most compliant between 20% to 80% of the vital capacity (VC) ([@b110-copd-1-381]; [@b2-copd-1-381]). To state this in a clearer way, the elastic work of breathing is minimized by maintaining tidal volume within the 20%--80% of the VC range. In COPD there are different forms and degrees of damage to the alveolar wall resulting in pathophysiological changes in the lung elastic recoil. These changes might reduce the amount of pressure required to achieve a specific change in volume ([@b30-copd-1-381]; [@b180-copd-1-381]), or simply shift the normal relationship upwards near passive FRC ([Figure 1](#f1-copd-1-381){ref-type="fig"}) ([@b184-copd-1-381]). There is limited information about passive elastic recoil characteristics of the lung and chest wall during exercise, but at least in healthy subjects, they remain essentially unchanged, or decrease slightly ([@b193-copd-1-381]; [@b217-copd-1-381]). Therefore total lung capacity (TLC) does not change significantly during physical activity either in normal subjects or in COPD patients ([@b193-copd-1-381]).

While the P--V relationship determines the attainable volume extremes for a given muscular pressure, the actual volume change in a given amount of inspiratory or expiratory time depends on the pressure--flow (P--F) relationship, which is highly dependent on the airways resistance (in a linear system, the volume at the time tx \[Vtx\] is given by the expression
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where P is the pressure applied, C the compliance of the system, tx the time elapsed, and R the resistance. The product RC is the time constant, which determines the speed of the change), as can be seen in [Figure 2](#f2-copd-1-381){ref-type="fig"}. During inspiration, even when inspiratory resistances are high, flow down the airways can be increased by increasing the force of inspiratory muscle contraction up to its maximum capacity ([@b218-copd-1-381]). The same is true during expiration at relative low pressures, but during forced expiration in both normal and COPD, increments in alveolar pressure (generated by increasing muscle effort) produce progressively smaller increments in expiratory flow, until flow ultimately reaches a plateau ([Figure 3](#f3-copd-1-381){ref-type="fig"}) where it is independent of any increase of driving pressure ([@b72-copd-1-381]). This phenomenon is called flow limitation and it seems to be related to the dynamic compression of the intra-thoracic airways at a segment progressively distal as lung volume decreases ([@b59-copd-1-381]). The resulting increase in airways resistance offsets the pressure generated by the additional increase in muscular effort, and therefore expiratory flow is actually largely independent of muscle effort and is determined by the respiratory system elastic recoil. Elastic recoil of the system is proportional to lung volume and the expiratory airways conductance (ie, the inverse of resistance) ([@b74-copd-1-381]). Respiratory mechanics in COPD are characterized by both elevated inspiratory and expiratory resistance to airflow ([@b109-copd-1-381]; [@b31-copd-1-381]; [@b3-copd-1-381]). An increased inspiratory airflow resistance can be compensated by augmenting the activation of the inspiratory muscles ([@b75-copd-1-381]), but the increased expiratory resistance, together with the reduced lung elastic recoil present in these patients, further limits expiratory flow ([@b73-copd-1-381]). This is physiologically much more deleterious because expiration is primarily effort independent ([Figure 3](#f3-copd-1-381){ref-type="fig"}), and cannot be compensated by increasing expiratory muscle effort ([@b159-copd-1-381]). The consequence in COPD is that the time needed for lung units to empty their volume and achieve their passive equilibrium point is significantly increased and many of them do not reach their relaxation volume before a new inspiration is initiated. As a result, part of the gas that would have been expired in a normal lung remains "trapped" (ie, more gas remains inside that what would be if those units were not altered) and the alveolar pressure at the end of the expiration is higher than the atmospheric pressure (intrinsic PEEP) ([@b163-copd-1-381]; [@b219-copd-1-381]). In young healthy subjects RV is about 25% of the TLC, and FRC is about 50% of the TLC ([@b192-copd-1-381]). In older healthy subjects, RV and FRC are about 30% and 55% of TLC respectively ([@b192-copd-1-381]). In COPD, values of RV and FRC are increased to values as high as 70% and 85% of the TLC, respectively ([@b49-copd-1-381]). Since tidal breathing is performed at FRC, COPD must breathe at volumes that are very close to TLC where the system is much less distensible ([Figure 1](#f1-copd-1-381){ref-type="fig"}).

During exercise minute ventilation must increase to meet the increased metabolic demands. This is achieved by increasing both the tidal volume (V~T~) and the respiratory frequency (f~R~), what means that the expiratory time necessary to reach passive FRC or below is reduced. In normal young subjects expiratory flow is fast enough to decrease end-expiratory lung volume (EELV) up to 0.5--1L below the resting FRC with increasing work. This is due to the activation of expiratory muscles ([@b163-copd-1-381]; [@b69-copd-1-381]). The decreased EELV not only allows increasing V~T~ within the most compliant part of the P--V relationship, but also has a beneficial inspiratory effect because, as the expiratory muscles relax, the passive tendency of the respiratory system below FRC is towards inspiration. In older subjects, EELV also decreases during moderate exercise, but thereafter, tends to increase back to near resting levels ([@b81-copd-1-381]). In COPD, due to the increased flow limitation, more and more units are unable to empty their gas as expiratory time decreases when the respiratory rate increases, and EELV typically rises ([Figures 1](#f1-copd-1-381){ref-type="fig"} and [4](#f4-copd-1-381){ref-type="fig"}) ([@b73-copd-1-381]; [@b60-copd-1-381]; [@b161-copd-1-381]; [@b42-copd-1-381]; [@b163-copd-1-381]; [@b8-copd-1-381]; [@b219-copd-1-381]; [@b216-copd-1-381]; [@b39-copd-1-381]; O'Donell et al 2001; [@b140-copd-1-381], [@b141-copd-1-381]; [@b130-copd-1-381]; [@b165-copd-1-381]) in spite of expiratory muscles activity ([@b42-copd-1-381]; [@b219-copd-1-381]). This temporary increase in EELV in COPD above its baseline (admittedly already elevated) value is termed DH. The extent of DH depends on the degree of expiratory flow limitation, the prevailing ventilation, the breathing pattern for a given ventilation, and is inversely related to the level of resting lung hyperinflation ([@b129-copd-1-381]; [@b165-copd-1-381]).

Muscle function
---------------

To move the air into the alveoli, sufficient force must be exerted by the respiratory muscles to expand the lungs and the chest wall. In addition, respiratory muscles must overcome the resistance and inertia in the system so that air will flow into the airways. This force is provided by the respiratory muscles and, thus, breathing is the results of their cyclic activation. Whether the net force is inspiratory or expiratory will depend on the balance between the pressure generated by the muscles and the elastic recoil of the respiratory system. The maximum inspiratory and expiratory pressures that the respiratory muscles are able to generate are related to several factors such as age ([@b18-copd-1-381]), muscle training ([@b94-copd-1-381]), the integrity of the inervation ([@b61-copd-1-381]) and, more important for the present discussion, of the length and shape (usually termed as "configuration") of the respiratory muscles, and particularly of the diaphragm (Marshall 1962). According to the Laplace's relationship (the Laplace relationship establishes the relationship between the pressure generated across a curved surface "P", the tension of the surface "T" and its radius "r": P=T/r), the less curved a surface is, the lower the pressure difference created across it. Thus at high lung volumes, a given neural output would be likely to cause less change in trans-diaphragmatic pressure than at low lung volumes. Furthermore, inspiratory muscles are able to generate less pressure for a given neural input because of their length--tension relationship ([@b90-copd-1-381]; [@b186-copd-1-381]; [@b157-copd-1-381]). The ability of the respiratory muscles to sustain a given level of pressure output (endurance) is defined by its pressure time index (PTI) ([@b109-copd-1-381]; [@b13-copd-1-381], [@b14-copd-1-381])
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Where "Pimus" is the inspiratory muscular pressure needed to achieve a certain displacement of the respiratory system, "MIP" is the maximum inspiratory pressure, "Ti" the inspiratory time and "Ttot" the total respiratory time. Thus the PTI is determined to a considerable degree by how high MIP is, and the fraction of MIP required to sustaining a given V~T~. MIP decreases as lung volume increases, while maximum expiratory pressure changes in the opposite direction ([@b2-copd-1-381]), therefore at high volumes a greater fraction of maximum effort is required to generate the same pressure. Paradoxically, thus, while flow limitation is primarily an expiratory phenomenon, its consequences are mainly suffered by the inspiratory muscles because expiratory muscles cannot appreciably increase flow ([Figures 3](#f3-copd-1-381){ref-type="fig"}) ([@b73-copd-1-381], [@b74-copd-1-381]; [@b72-copd-1-381]; [@b163-copd-1-381]; [@b59-copd-1-381]) to force the emptying of the lungs. In consequence the volume at which the respiratory system has to operate is increased ([@b73-copd-1-381]; [@b60-copd-1-381]; [@b161-copd-1-381]; [@b42-copd-1-381]; [@b163-copd-1-381]; [@b8-copd-1-381]; [@b219-copd-1-381]; [@b216-copd-1-381]; [@b39-copd-1-381]; [@b129-copd-1-381]; [@b140-copd-1-381], [@b141-copd-1-381]; [@b130-copd-1-381]; [@b165-copd-1-381]) and hence the elastic work needed for a given displacement of the thorax ([Figure 1](#f1-copd-1-381){ref-type="fig"} and [4](#f4-copd-1-381){ref-type="fig"}) ([@b30-copd-1-381]; [@b180-copd-1-381]; [@b110-copd-1-381]; [@b184-copd-1-381]; [@b217-copd-1-381]; [@b2-copd-1-381]). Second inspiratory muscles have to generate a substantial inspiratory pressure (intrinsic PEEP) before inspiratory airflow can occur. PEEP behaves actually as an inspiratory threshold load ([@b152-copd-1-381]; [@b163-copd-1-381]; [@b65-copd-1-381]; [@b219-copd-1-381]), and finally, as we have seen above, at high lung volume efficacy of respiratory muscles as pressure generators is greatly reduced (Marshall 1962; [@b90-copd-1-381]; [@b186-copd-1-381]; [@b157-copd-1-381]).

Clinical consequences of dynamic hyperinflation
===============================================

Exercise limitation
-------------------

Patients with COPD characteristically show a poor exercise performance which is manifested as marked reduction in peak oxygen uptake and decreased endurance to submaximal levels of exercise ([Table 1](#t1-copd-1-381){ref-type="table"}) ([@b51-copd-1-381]; [@b24-copd-1-381]; [@b130-copd-1-381]). The origin of this poor exercise tolerance is multifactorial and includes abnormal lung mechanics, impaired pulmonary gas exchange, destruction of the pulmonary vascular bed, impaired cardiac function and peripheral muscle dysfunction ([@b51-copd-1-381]; [@b24-copd-1-381]; [@b130-copd-1-381]). Dynamic hyperinflation has a detrimental impact on exercise tolerance via three important physiopathological mechanisms. The relatively rapid shallow breathing pattern in COPD compared with healthy subjects, reflects the mechanical constraints on tidal volume expansion, which has an exaggerated frequency-dependency in COPD, f~R~ increases with exercise in COPD up to a maximum of about 25--35min^−1^ ([@b39-copd-1-381]; [@b123-copd-1-381]; [@b165-copd-1-381]). At increased respiratory rates, the inversely proportional decrease in expiratory time, even though there is a slight reduction of Ti/Ttot to 0.40--0.45 ([@b39-copd-1-381]; [@b165-copd-1-381]), and as result of the decreased expiratory time further DH ensues. When EELV reaches approximately 0.5L tidal volume, ventilation reaches a plateau (or even a slight decreases), exercise soon stops ([Figure 5](#f5-copd-1-381){ref-type="fig"}) ([@b129-copd-1-381]; [@b165-copd-1-381]). This encroachment of tidal volume not only hampers the ventilatory response to the metabolic load of exercise, it contributes to reducing the efficiency of ventilation (ie, increases the dead space) as well ([@b51-copd-1-381]). This effect, together with the augmented mechanical impedance of the respiratory system results in an increased work and O~2~ cost of breathing at any given metabolic load compared with age-matched healthy controls, ([@b176-copd-1-381]; [@b46-copd-1-381]; [@b185-copd-1-381]; [@b106-copd-1-381]; [@b196-copd-1-381]). In one study this additional oxygen cost has been found to be as much as 40% of the total oxygen uptake ([@b95-copd-1-381]).

Dyspnea
-------

Dyspnea is believed to be the unpleasant awareness of the respiratory muscle effort. As it was discussed above DH both increases the pressure changes needed to achieve a given tidal volume and decreases the ability of the respiratory muscles to generate this pressure (Marshall 1962; [@b90-copd-1-381]; [@b186-copd-1-381]; [@b157-copd-1-381]). This then increases the amount of pressure needed to achieve a certain tidal volume with respect to the maximum pressure ([@b89-copd-1-381]). The change in lung mechanics during exacerbation of COPD has been show to be directly related to dyspnea during spontaneously breathing. The improvement in operating lung volumes (ie, increase in inspiratory capacity \[IC\]) as the exacerbation resolves is correlated to symptomatic improvement and reductions in dyspnea ([@b146-copd-1-381]; [@b190-copd-1-381]). While COPD patients do not usually stop exercise at higher rates of perceived dyspnea than normal subjects, the ratio of symptoms to the metabolic load and minute ventilation are usually increased ([@b88-copd-1-381]; [@b66-copd-1-381]). In these patients there exists a close correlation between breathlessness during exercise and DH ([@b138-copd-1-381]; [@b47-copd-1-381]; [@b165-copd-1-381]; [@b208-copd-1-381]). In a recent study, arm exercise in COPD has been found to produce DH as well ([@b57-copd-1-381]).

Hypoventilation/hypercapnia
---------------------------

The increase in inspiratory and expiratory airway resistance characteristic of COPD would cause only minor problems in ventilatory function (ie, for the respiratory muscles) if the disease, through expiratory flow limitation did not cause dynamic hyperventilation, and its corollaries that include increased elastic recoil, encroached tidal volume, the threshold load imposed by intrinsic PEEP, and the changes in the configuration of the thorax that greatly reduce their ability to generate pressure. When COPD patients with expiratory flow-limitation need to increase their respiratory rate to increase minute ventilation, there is potential for inspiratory muscle failure due to DH ([Table 1](#t1-copd-1-381){ref-type="table"}). During exacerbations, the inflammatory process, the ventilation/perfusion (V′~A~/Q′) mismatching, increased airflow resistance, and DH, expose the respiratory muscles to the risk of fatigue, eventually leading to ventilatory pump failure and hypercapnia ([@b175-copd-1-381]). DH is one of the major mechanisms involved in the development of hypercapnia and (secondarily hypoxemia) during exercise in COPD patients ([@b39-copd-1-381]; [@b133-copd-1-381]).

Cardiac dysfunction
-------------------

Lung hyperinflation and excessive expiratory muscle recruitment can impair venous return and reduce right ventricular preload in COPD ([@b101-copd-1-381]; [@b113-copd-1-381]). Moreover, large intrathoracic pressure swings generated during exercise to overcome the increased elastic and resistive loads may result in left ventricular dysfunction (increased left ventricular afterload) ([@b143-copd-1-381]; [@b114-copd-1-381]). Right ventricular afterload during exercise is also increased because of the increased pulmonary vascular resistance associated with breathing at lung volumes close to TLC ([@b170-copd-1-381]; [@b144-copd-1-381]).

Weaning failure
---------------

The incidence of EFL was very high in a small sample of patients with COPD receiving invasive mechanical ventilation for acute respiratory failure. In this series IC was lower in patients who failed weaning than those who were successfully weaned ([@b5-copd-1-381]).

Hypotension and barotrauma in the mechanical ventilated patient
---------------------------------------------------------------

Dynamic hyperinflation is a potential cause of hypotension and barotrauma in mechanically ventilated patients with EFLs ([Table 1](#t1-copd-1-381){ref-type="table"}). DH should be minimized by the use of bronchodilators and appropriately setting minute ventilation (higher tidal volumes, slower respiratory rate, higher I:E ratio) to maximize expiratory time ([@b182-copd-1-381]).

Exercise training
-----------------

Most rehabilitation programs are based on constant-load exercise (CLE) training, consisting of sustained exercise for 30--40min ([@b1-copd-1-381]). Generally, high-intensity training is argued to be needed for the improvement of exercise capacity ([@b26-copd-1-381]). Although patients with moderately severe COPD (mean forced expiratory volume in one second \[FEV~1~\] \>45% predicted) can tolerate high levels (80%) of their peak tolerance for several minutes ([@b119-copd-1-381]), more severe disease (FEV~1~ \<45% predicted) are unable to tolerate such high exercise intensities for long periods of time ([@b103-copd-1-381]). Together with peripheral muscle dysfunction, the major factor that limit exercise tolerance in these patients is the development of DH, and the concurrent mechanical constraints on ventilation that contribute importantly to perceived respiratory discomfort ([@b39-copd-1-381]; [@b165-copd-1-381]). Dynamic hyperventilation is evident even with short exercise bouts in interval training ([@b209-copd-1-381]). In one study, a correlation was found between resting hyperinflation (measured as RV/TLC%) and the increase in endurance time after 8 weeks of leg muscle rehabilitation ([@b167-copd-1-381]). In another study, IC was found as a significant predictor of the long term effects after a rehabilitation program, but in a multiple logistic regression model, only pressure of carbon dioxide (PaCO~2~) was identified as predictor for the maintenance of improvement in health-related quality of life over one year ([@b126-copd-1-381]).

Survival
--------

Certain variables closely linked to DH ([@b138-copd-1-381], [@b129-copd-1-381], [@b133-copd-1-381]; [@b39-copd-1-381]; [@b108-copd-1-381]) such as exercise capacity (maximal oxygen uptake) ([@b54-copd-1-381]; [@b20-copd-1-381]; [@b117-copd-1-381]; [@b70-copd-1-381]; [@b141-copd-1-381]) or 6 minute walking distance ([@b156-copd-1-381]), dyspnea ([@b29-copd-1-381]), and oxygen desaturation ([@b125-copd-1-381]; [@b70-copd-1-381]; [@b203-copd-1-381]) during exercise have been show to be powerful predictors of survival in COPD patients ([Table 1](#t1-copd-1-381){ref-type="table"}). A recent study of 689 COPD patients, with a mean follow up of 34 month, showed that the IC/TLC was an independent risk factor for mortality in subjects with COPD ([@b27-copd-1-381]). Using the criterion of IC/TLC \<25% with a mean follow up period of 34 months, the adjusted hazard ratio for death of any cause was 1.97 and 2.04 for death caused by acute respiratory failure ([@b27-copd-1-381]). In another study RV/TLC was also a prognostic factor for survival at 5 years but not independent of age, FEV~1~, and arterial oxygen pressure at maximal exercise ([@b203-copd-1-381]).

Therapeutic interventions directed to ameliorate dynamic hyperinflation
=======================================================================

The treatment of flow limitation and DH has a long history that goes back as far as the 19th century, but the recent recognition of the importance of DH has modified the target physiological variables that we use to evaluate the therapeutic interventions, such as bronchodilators or rehabilitation, and has led to a renewed interest in specific treatments such as the lung volume reduction surgery (LVRS). In this section we will discuss those therapies grouped according their target physiological variable.

Treatments that primarily decrease respiratory rate and increase V~T~
=====================================================================

Pursed-lip breathing
--------------------

Pursed-lip breathing (PLB) ([@b9-copd-1-381]) is aimed to reduce breathing frequency and to diminish the impact of intrinsic PEEP on respiratory muscles. PLB produces a substantial increase in V~T~ along with a reduced ventilatory rate and minute ventilation ([@b198-copd-1-381]; [@b116-copd-1-381]; [@b17-copd-1-381]). There is a direct relationship between the efficacy of PLB in reducing dyspnea and the effect on respiratory rate ([@b116-copd-1-381]). This technique is able to increase expiratory airways pressure thus inhibiting expiratory airways collapse ([@b78-copd-1-381]). It appears that patients that do not adopt PLB instinctively did not assume it naturally for long periods of time even when properly taught ([@b201-copd-1-381]). In a recent study imposed PLB did not improved 6 minute-walking distance, but improved the rate of dyspnea recovery to basal levels ([@b52-copd-1-381]). In another study, PLB reduced respiratory rate in patients with COPD during exercise on a cycle-ergometer, but the effect of imposed PLB on dyspnea were variable and related to the change that it promoted in the tidal volume and EELV ([@b188-copd-1-381]).

Peripheral muscle training
--------------------------

A number of studies have shown that leg training decreases respiratory rate during exercise (Cassaburi et al 1997; [@b168-copd-1-381]; [@b210-copd-1-381]; [@b56-copd-1-381]; [@b177-copd-1-381]), and three previous studies have directly analyzed the impact of leg training on DH at high intensity exercise. In two uncontrolled studies, a reduction of respiratory rate and an increase in IC was seen ([@b56-copd-1-381]; [@b160-copd-1-381]). In another controlled study, the same effect was seen after 8 weeks of leg training on a bike compared with no training in moderate to severe COPD ([@b166-copd-1-381]). In another study the opposite was observed ([@b151-copd-1-381]). However, this latter study included eight quite unusual COPD subjects (ie, 38 \[11\] years, FEV~1~ 3.5 (0.5) L and V O~2~ 2.86 (0.6) L min^−1^) that can not be regarded as a typical population of COPD patients. Arm training also reduced DH during arm exercise in a small uncontrolled study of COPD subjects ([@b57-copd-1-381]).

Oxygen
------

Several observations in nonhypoxemic COPD patients demonstrate the favorable effect of oxygen supplementation during exercise in COPD patients without clinically significant hypoxemia ([@b213-copd-1-381]; [@b36-copd-1-381]; [@b132-copd-1-381]). Endurance time increased with supplemental oxygen at several different inhaled concentrations of oxygen both in a small group (10) of severe mildly hypoxemic COPD patients and 7 healthy controls. In both groups oxygen reduced f~R~, dyspnea, and increased V~T,~ and endurance time in a dose-dependent fashion, but the effects were relatively larger in the COPD patients. In the healthy subjects, differences were only appreciable with F~I~O~2~ \> 0.5 or more. The improvement in endurance time was correlated with a decrease in EELV ([@b187-copd-1-381]). In a group of 18 severe COPD patients, oxygen reduced the degree of DH during recovery from exercise but did not reduce breathlessness compared with air, which suggests that lung mechanics may play a different role in the genesis of dyspnea during recovery from exercise ([@b189-copd-1-381]).

Opioids
-------

Opioids have been show to decrease dyspnea during exercise ([@b214-copd-1-381]; [@b97-copd-1-381]), but to our knowledge no study has addressed their effect on DH. One study reported a decrease in f~R~ for a given work-rate, and increases in V~T~ and ventilation were found ([@b98-copd-1-381]). The reported side-effects of opioids and their tendency to lead to tolerance and addiction preclude their use except in highly specific cases and end-of-life situations. Benzodiazepines do not seem to improve exercise capacity or dyspnea ([@b63-copd-1-381]) and have a deleterious effect on inspiratory muscle function, reducing both V~T~ and minute ventilation ([@b83-copd-1-381]).

Treatments that primarily reduce flow limitation
================================================

One of the most exciting aspects of the renewed interest in DH is the realization that bronchodilator drugs may significantly improve DH, and thus exercise tolerance ([@b15-copd-1-381]; [@b134-copd-1-381]), and that these changes may not be detectable by isolated resting pulmonary function test (PFT) measurements like the FEV~1~ ([@b64-copd-1-381]).

Bronchodilators
---------------

Several studies have addressed the effect of bronchodilators on lung hyperinflation ([Table 2](#t2-copd-1-381){ref-type="table"}). In 13 COPD patients randomly assigned to receive either inhaled placebo or salbutamol, the bronchodilator caused significant increase in both FEV~1~ and forced vital capacity (FVC). There was also a significant reduction in the peak exercise EELV/TLC and esophageal inspiratory pressure/peak inspiratory esophageal pressure. Moreover a significant reduction in breathlessness that correlated with changes in end-inspiratory lung volume/TLC was also seen ([@b15-copd-1-381]). In a retrospective review of 281 patients with TLC \>133% predicted and 676 with TLC between 115% to 133% predicted, 200μg of salbutamol produced a significant reduction of FRC, RV, and increased the IC and FVC. The FEV~1~ improved in only a minority (around 30%). If lung volume measurements are also considered, the overall bronchodilator response may improve up to 76% of the severely hyperinflated group and up to 62% of the moderately hyperinflated ones. Changes in volumes correlated poorly with changes in maximal airflows. Surprisingly TLC was also slightly reduced (about 2.5%) by bronchodilators suggesting that the changes in airways resistance or the familiarity with the method may have affected the constant volume plethysmographic technique used to measure volumes ([@b121-copd-1-381]). Unless salbutamol had produced changes in the ability to generate force by the respiratory muscles, or the elastic properties of the lung, both of which it are unlikely. [@b169-copd-1-381] found that the use of salmeterol reduced not only dyspnea but improved lung function in patients with COPD. Patients showed an increase in FVC, a reduction in RV and FRC, and no changes in TLC following inhalation of salmeterol. [@b19-copd-1-381] studied 20 COPD, 11 with flow limitation using the negative expiratory pressure before and after the inhalation of 400μg salbutamol. Following salbutamol, IC did not change in non-flow limited patients but increased significantly in the flow-limited ones. Dyspnea decreased in relation to IC at rest even in the absence of a significant improvement in FEV~1~. Di Marco and colleagues (1993) found that in patients with decreased baseline inspiratory capacities; there was a much greater increase of IC after administration of bronchodilators such as salbutamol, formoterol, salmeterol, and oxitropium. This increase correlated closely with improvement in a sensation of dyspnea. [@b28-copd-1-381] evaluated the long-term effects (4 weeks) of 18 μg/day of tiotropium. Significant similar improvements in the area under the curve of FEV~1~ and IC and over the curve in FRC were observed, reflecting sustained improvements in hyperinflation. [@b128-copd-1-381] and [@b102-copd-1-381] conducted a multicentric study on the long-term effects (6 weeks) of 18μg/day of tiotropium. Tiotropium reduced lung hyperinflation indices at rest and during exercise, and improved exercise tolerance 8 h after the inhalation of the drug. Finally [@b128-copd-1-381] studied the effects of 50μg of inhaled salmeterol. After salmeterol versus placebo at rest, IC increased and FRC decreased at a standardized time during exercise. In addition, IC and V~T~ increased and dyspnea decreased. Significant increments in peak ventilation, oxygen uptake, and the duration of the incremental test were also seen. Man and colleagues (2004) studied 16 patients with "irreversible" severe COPD after two weeks of treatment with 50μg of salmeterol twice a day. Salmeterol significantly reduced the transdiaphragmatic pressure-time product, DH, and Borg scores during endurance treadmill walk, however there was no significant change in exercise endurance time.

In contrast with the results of [Table 2](#t2-copd-1-381){ref-type="table"}, bronchodilators have shown wide variations in regards to changes in exercise capacity ([@b96-copd-1-381]). Earlier negative studies may have included subjects whose exercise capacity was not ventilatory-limited. In fact, several studies in [Table 2](#t2-copd-1-381){ref-type="table"} demonstrate that the effects of bronchodilators are larger in those with flow limitation than in those without flow limitation. Flow limitations are a major determinant of exercise capacity ([@b39-copd-1-381]). Alternatively, they may have included a great proportion of patients that were not responsive to bronchodilators (about 1/3 of COPD patients do not improve either FEV~1~ or IC with bronchodilators) ([@b121-copd-1-381]). Third, some of those studies may have used insufficient doses and only a few included long-acting bronchodilators, and in particular, none included tiotropium ([@b96-copd-1-381]). Fourth, most studies included 6 minute walking tests to measure exercise capacity; however, 6 minute walking distance is sensitive to a learning effect. Two training sessions are necessary to eliminate a learning effect in walking tests ([@b87-copd-1-381]; Knox et al 1988). Constant work load tests appears to be more appropriate than other tests, as they allow for placebo-controlled comparisons of symptoms and physiological parameters, including exercise endurance time at a standardized work rate or power output ([@b128-copd-1-381]). Cycle exercise endurance testing, combined with measurements of exertional dyspnea, ventilation, and dynamic operating lung volumes, has been shown to be reliable, reproducible, and responsive to the intervention ([@b139-copd-1-381]; [@b167-copd-1-381]; [@b128-copd-1-381]).

Heliox
------

Helium is gas that is less dense and more viscous than air. Its lower density can decrease airway resistance in the absence of any anatomical change. Therefore, the greatest theoretical benefit of heliox would be achieved by decreasing turbulent flow in large airways and at branch points in the tracheobronchial tree.

Heliox is unlikely to be of substantial benefit in adults with asthma. A systematic analysis pooled results from seven trials enrolling nearly 400 patients and found no significant improvement in recovery of pulmonary function in patients with acute asthma who were treated with heliox ([@b172-copd-1-381], [@b173-copd-1-381]). One study examined the effects of heliox (80:20) on gas exchange, breathing pattern, respiratory mechanics, and gas distribution in patients with stable, but severe, COPD ([@b195-copd-1-381]). Heliox was not associated with significant changes in minute ventilation or breathing pattern, however a 15% reduction in FRC which increased back to baseline after a return to air breathing was observed. On the other hand another small trial found no change in DH among COPD patients ([@b148-copd-1-381]). In addition, the high cost and limited availability of heliox make its clinical use more difficult. In another study, researchers used an esophageal balloon in recently extubated patients without significant lung disease to quantify intrathoracic pressure swings and estimate the work of breathing ([@b79-copd-1-381]). Fifteen of 18 patients exhibited a drop in their work of breathing, although gas exchange parameters were unchanged. The patients also reported decreased dyspnea while breathing heliox.

The clinical effects of heliox in the absence of positive pressure ventilation have not been well studied. Fifty normoxic COPD with an acute exacerbations were prospectively randomized in the emergency room to receive either heliox (70:30), or air as the driving gas for updraft nebulization of a mixture of salbutamol and ipratropium bromide The base-line FEV~1~ was 44% There were no significant differences in the change of FEV~1~ between the two groups by either the 1 h or 2 h time point. Lung volume measurements were not made, but the improvement in forced expiratory flow over the middle half of the FVC (FEF25%--75%) was significantly greater in the heliox group, the authors considered that this improvement had no clinical significance, but measures of dyspnea or recovery were not provided ([@b37-copd-1-381]). A retrospective review of 81 patients presenting to the emergency department with COPD and hypercarbic respiratory insufficiency found a significant reduction in the rates of intubation (8% vs 50%) and in-hospital mortality (3% vs 24%) in the patients who received heliox as compared with control patients ([@b55-copd-1-381]).

Several trials have compared noninvasive positive pressure ventilation (NPPV) combined with either air or heliox in patients with exacerbations of COPD. In one well-designed trial, patients with acute exacerbations of COPD were treated with low or high pressure NPPV in combination with heliox or oxygen-supplemented air ([@b80-copd-1-381]). Differences in breathing pattern, work of breathing, and gas exchange were measured in nine patients using an esophageal balloon technique. Heliox was not associated with changes in breathing pattern, whereas high pressure NPPV produced significant increases in tidal volume and minute ventilation. Heliox was associated with a reduction in PaCO~2~ and improvement in all measured indices of respiratory effort and work. The beneficial effects on the measured variables were further increased when high pressure NPPV was combined with heliox, compared with the low pressure/air group. The authors suggest that the addition of heliox to NPPV may allow a larger number of patients to benefit from NPPV. In addition, heliox may allow the use of lower levels of pressure support, which could reduce complications and patient discomfort resulting from high pressures and flow rates ([@b80-copd-1-381]). A crossover study monitored the effects of NPPV plus either heliox (70:30) or oxygen (FiO~2~ 0.30) on gas exchange and dyspnea in 19 patients with severe COPD ([@b82-copd-1-381]). The use of heliox decreased PaCO~2~, reduced dyspnea, and favorably changed the breathing pattern of patients. Peak inspiratory flow rates were higher, while inspiratory time and the ratio of inspiratory time to respiratory cycle length were both decreased. All of these findings suggest a reduced work of breathing. A third series of 23 intubated patients with COPD and respiratory failure found that the administration of heliox significantly reduced intrinsic PEEP, trapped lung volume, and peak and mean airway pressures ([@b197-copd-1-381]). Similar findings were noted in a second small study of 12 patients recovering from acute exacerbations of COPD. In this randomized prospective crossover trial, heliox decreased the resistive work of breathing and intrinsic positive end-expiratory pressure (auto-PEEP) without changing the breathing pattern ([@b40-copd-1-381]).

One study examined the impact of heliox on pulmonary function in ten aging runners with very mild COPD during cardiopulmonary exercise testing. Heliox was associated with an increase in minute ventilation, in the absence of any change in the metabolic cost of breathing ([@b7-copd-1-381]). Another work studied 12 patients with severe COPD (FEV~1~ 38\[10\]% of predicted) comparing heliox (79:21) with air. Exercise endurance increased significantly and peak ventilation time with heliox. This was associated with a significant reduction in lung DH and dyspnea at isotime. The reduction in dyspnea correlated significantly with the increase in IC induced by heliox ([@b145-copd-1-381]).

Increasing elastic recoil
-------------------------

Although there are no currently available treatments to return the lung to its normal structure once it has been damaged by the inflammatory process (like COPD), this may indeed be possible in the future using stem cells ([@b142-copd-1-381]; [@b194-copd-1-381]). Stem cells may indeed improve the compliance characteristics of the lung. However, at this time lung volume-reduction surgery (LVRS; a surgical or bronchoscopic procedure that involves resection or exclusion of the most severely affected regions of diseased lung tissue) in patients with diffuse emphysema, may improve lung function by increasing elastic recoil of the lung, the effective pressure driving maximal expiratory flow airway, and the conductance of the airways by augmenting the radial traction of their alveolar attachments. Hence it may improve flow proportionately at all areas of the lung and secondarily reduce hyperinflation ([@b21-copd-1-381]; [@b174-copd-1-381]; [@b48-copd-1-381]; [@b76-copd-1-381]). This surgery was initially described in the late 1950s ([@b21-copd-1-381]). The persistent air leaks that limited early success have been diminished considerably by the recent surgical advances, which has increased interest in this procedure and led to its greater availability ([@b212-copd-1-381]; [@b32-copd-1-381]; [@b85-copd-1-381]; [@b68-copd-1-381]; [@b22-copd-1-381]).

Several randomized trials have compared LVRS with optimal medical treatment ([@b53-copd-1-381]; [@b49-copd-1-381]; [@b112-copd-1-381]) and by far the largest of these was the National Emphysema Treatment Trial (NETT) ([@b49-copd-1-381]). NETT enrolled over 1200 patients with severe emphysema who underwent baseline assessment followed by six months of mandatory pulmonary rehabilitation. The patients were then randomly assigned to surgical or continued medical therapy, with plans for three-year follow-up. In this study high risk patients were defined as having: FEV~1~ \< 20% and either diffusing capacity of the lung for carbon monoxide (DL~CO~) \< 20% predicted or homogeneous changes on chest computer tomography ([Table 3](#t3-copd-1-381){ref-type="table"}). The 30-day mortality was 16% in the surgical group compared with no deaths in the medically managed group ([@b120-copd-1-381]). In the remainder of the study, while there was a significant improvement in exercise capacity in the surgical group (the same has been found in another study \[[@b45-copd-1-381]\]), there was no difference in the total mortality rate at the end of follow-up with surgical or medical therapy (9% vs 10% per year with medical therapy), however, the 90-day mortality was significantly higher with surgery (5.2% vs 1.5%) ([@b49-copd-1-381]). Only the subset of patients with upper lobe predominant emphysema and low exercise capacity (24%) had a significant reduction in total mortality with surgery (7% vs 15% per year, risk ratio 0.47). In this study, low exercise capacity was defined as less than 40% of the gender--specific predicted work rate (40 W in men and 25 W in women) ([@b49-copd-1-381]).

Recently LVRS has been attempted by bronchoscopically placing one-way valves in airways associated with areas of severe emphysema and hyperexpansion. These valves allow air and secretions to move from alveoli to the central airways, but prevent air from entering the distal airspaces. Over time, this results in collapse of the affected regions. Experience in humans is limited, but one series of 19 patients who underwent unilateral valve placement noted decreased air-trapping and improvement in exercise tolerance one month after the procedure ([@b71-copd-1-381]).

LVRS produces less functional improvement than lung transplant ([@b50-copd-1-381]), but since patients who undergo LVRS are not automatically excluded from receiving a subsequent lung transplant both treatments might be sequentially applied ([@b118-copd-1-381]).

Large bullae which can potentially benefit from surgical resection are uncommon clinically. An important challenge for the clinician is to select the patient for bullectomy who can have the greatest benefit with the lowest morbidity and mortality. The most common indication for bullectomy is severe dyspnea in the setting of a large bulla occupying at least 30%--50% of the hemithorax. Another indication is history of a pneumothorax. The physiologic outcome after surgery is determined largely by the size of the bulla and the severity of the underlying emphysema, and patients with severe generalized emphysema tend to do poorly ([@b122-copd-1-381]). The surgical risk is increased when the FEV~1~ is less than 40% of predicted, and the presence of severe dyspnea, a markedly reduced FEV~1~, hypercapnia, or cor pulmonale makes the risk of surgery almost prohibitive ([@b62-copd-1-381]).

Relieving the inspiratory threshold load
========================================

Pursed-lip breathing
--------------------

We have reviewed the effects of PLB above. In addition to reducing respiratory rate, it likely reduces dynamic airways compression by generating an extratoracic resistance and thus creates PEEP.

Positive end-expiratory pressure
--------------------------------

Intrinsic PEEP is frequent in mechanically ventilated patients with obstructive airways disease. Several studies indicate that in patients with flow limitation by dynamic airway collapse, the application of small amounts of external PEEP can be beneficial since intrinsic PEEP can account for about one-third of the total work of breathing ([@b34-copd-1-381]). Hyperinflation may not be affected when applied PEEP is below 85% of the measured auto-PEEP ([@b171-copd-1-381]), however not all patients with auto-PEEP and DH have expiratory flow limitation ([@b6-copd-1-381]) and care has to be taken to reduce the impact of a narrow diameter or kinked endotracheal tube, inspisated secretions, exhalation/PEEP valves, and asynchrony due to pain or agitation. The incidence of expiratory flow limitation has been reported to be as high as 93% upon initiation of mechanical ventilation, but it is reduced by half over time with therapy ([@b5-copd-1-381]). It seems to be more likely when patients are supine instead of semirecumbent ([@b204-copd-1-381]).

A recent meta-analysis of 7 studies including a total of 65 patients with COPD shows a modest beneficial effect of ventilatory support on exercise tolerance as well (van 't [@b205-copd-1-381]), probably in part because continuous positive airway pressure (CPAP) unloads inspiratory muscles from the inspiratory threshold load imposed by intrinsic PEEP ([@b152-copd-1-381]; [@b65-copd-1-381]; [@b155-copd-1-381]; [@b100-copd-1-381]). In severe COPD patients CPAP of 0.5kPa resulted in a significant reduction in dyspnea and an increase in exercise endurance time ([@b135-copd-1-381]; [@b136-copd-1-381]), however excessive CPAP increases the perception of breathing effort ([@b135-copd-1-381]) and hence it should be titrated individually. Inspiratory pressure support (IPS) a form of pressure-targeted mechanical ventilation which each breath is patient triggered and supported has been shown to improve exercise tolerance ([@b86-copd-1-381]; [@b104-copd-1-381]; [@b93-copd-1-381]; [@b158-copd-1-381]; [@b206-copd-1-381]) and reduce lactate production ([@b158-copd-1-381]). Proportional assisted ventilation, a mode of partial ventilatory assistance adapted to the intensity and timing of spontaneous ventilatory pattern by providing inspiratory pressure in proportion to a patient's spontaneous effort, has been shown also to increase exercise tolerance ([@b43-copd-1-381]; [@b16-copd-1-381]). The role of pressure support in severely limited COPD patients is not yet clear. In a recent double-blind controlled study of 29 patients with moderate-severe COPD and ventilatory limitation during an incremental exercise test, 37 patients were exercised with either IPS 1kPa (19 subjects) versus 0.5kPa (18 subjects) in the control group. Statistically significant differences were found in favor of the IPS in shuttle walking distance, cycle endurance, and reduction in minute ventilation during exercise (van't [@b206-copd-1-381]).

Measuring flow limitation and dynamic hyperinflation
====================================================

Spirometry
----------

Spirometry is a central parameter in the diagnosis and staging of COPD, yet it is poorly correlated with dyspnea and exercise capacity ([@b67-copd-1-381]; [@b10-copd-1-381]) and has limited individual value to predict the increase in exercise tolerance in patients with severe COPD ([@b202-copd-1-381]; [@b134-copd-1-381]), however resting IC seems to be better index of exercise capacity ([@b39-copd-1-381]) and changes in IC are better indicator of the reduction of dyspnea and exercise tolerance ([@b169-copd-1-381]; [@b64-copd-1-381]; [@b19-copd-1-381]; [@b28-copd-1-381]; [@b128-copd-1-381]; [@b190-copd-1-381]), furthermore the use of IC as an adjunct criterion for a bronchodilator test apparently increases the sensitivity to detect functional changes clinically relevant ([@b121-copd-1-381]; [@b146-copd-1-381]). Although there is no defined criterion to evaluate changes in IC ([@b150-copd-1-381]), changes after bronchodilators have been usually larger than 15% ([@b169-copd-1-381]; [@b64-copd-1-381]; [@b19-copd-1-381]; [@b28-copd-1-381]; [@b128-copd-1-381]). Other useful indexes of air trapping are FRC, RV, and their relationship with TLC ([@b41-copd-1-381]), although they are more complex to obtain and not as widely available as spirometry.

Flow volume loops
-----------------

The conventional method used to detect expiratory flow limitation using tidal breathing was one proposed by [@b72-copd-1-381]. It consists of superimposing a flow--volume loop of a tidal breath within a maximum flow--volume curve. Expiratory flow limitation is not present when the patient breathes below the maximal expiratory flow--volume curve ([@b164-copd-1-381]). This method to detect expiratory flow limitation has several methodological deficiencies such as intrathoracic gas compression artefacts (which only can be detected with a constant pressure body plethysmograph ([@b77-copd-1-381]), incorrect alignment of tidal with maximal expiratory flow--volume curve considering the TLC as a fixed reference point, which is not always valid ([@b217-copd-1-381]; [@b35-copd-1-381]). Respiratory mechanics and the intrathoracic pressure swinging are different during the tidal and maximal expiratory efforts and exercise may result in changes in airways tone ([@b11-copd-1-381]). Another important limitation of the conventional method is that it requires patient cooperation.

The negative expiratory pressure technique
------------------------------------------

The negative expiratory pressure technique (NEP) method is based on the principle that the increase in pressure caused by NEP should result in increased expiratory flow. By contrast, in flow-limited subjects, application of NEP should not change the expiratory flow ([@b92-copd-1-381]). For technical details we refer the reader elsewhere. This method does not require FVC maneuvers, collaboration on the part of the patient, or use of a body plethysmograph, and can be used during spontaneously breathing subjects during exercise ([@b23-copd-1-381]).

Measurement of dynamic hyperinflation
-------------------------------------

Since TLC remains essentially unaltered during exercise ([@b193-copd-1-381]; [@b217-copd-1-381]) changes in EELV during exercise can be reliably tracked by serial IC measurements ([Figure 5](#f5-copd-1-381){ref-type="fig"}). Exercise IC measurements are reproducible, provided care is taken with their measurement. In one study of 29 patients the variability coefficient was 17% at rest and approximately 20% during exercise with intra-class correlation coefficients of 0.77 and 0.73 respectively ([@b134-copd-1-381]). In another study of 15 patient esophageal pressures were found reproducible during IC maneuvers during exercise at different work-rates, the reduction in IC during exercise correlates well with esophageal balloon-derived measurements of dynamic compliance ([@b127-copd-1-381]). In another study, three methods of measuring IC were tested in 10 severe COPD subjects. IC calculated, after correction of the expiratory part of the signal, as the difference between the mean EELV of the six breaths that preceded the IC prompt and the peak inspiratory volume was found to be the most reproducible method ([@b44-copd-1-381]). In an unpublished multicentric study of 463 patients with moderate to severe COPD, the intra-class correlation of exercise IC measurements during serial exercise tests exceeded 0.85 ([@b128-copd-1-381]). The extent of the reduction in IC with exercise in COPD is variable. In a population of 105 patients with moderate to severe COPD, IC at end-exercise was reduced by 20% of its already-reduced resting value ([@b129-copd-1-381]). In another smaller group of 27 severe COPD patients a similar reduction was found at maximum ventilation at the end of high intensity exercise ([@b165-copd-1-381]). Similar changes were found in severe COPD in 15 severe COPD ([@b216-copd-1-381]). However, guidelines for standardization of IC measurement have not yet been issued. Recently a new complex method called optoelectronic plethysmography has been developed for research purposes ([@b4-copd-1-381])

Conclusion
==========

Flow limitation and DH are crucial pathophysiological mechanisms in the development of exercise intolerance, dyspnea, and respiratory failure in COPD patients. As the disease advances with progression of symptoms and impairment, the flow limitation and DH proportionally worsens. Several methods of treatment may palliate its impact of flow limitation and DH on the patient, including physical therapy, bronchodilators, ventilatory support, oxygen, heliox, or surgery. Measurement of DH may be done indirectly by spirometry or by more direct approaches that have known limitations or are not widely available. Clinical use is limited by the lack of a standard method to measure DH or flow limitation during exercise.

![Pressure volume relationship of the passive respiratory system. Lower and upper boundaries of the elastic recoil pressure--volume relationship of the respiratory system in healthy subjects (\-\--), in patients with narrowed airways (---), and in patients with loss of lung elastic recoil (·····). The loops represent tidal breathing at rest (---) and during exercise (·····).\
**Abbreviations:** FRC, functional residual capacity; VC, vital capacity.](copd-1-381f1){#f1-copd-1-381}

![Effects of time and resistance on the change in expiratory volume. Rates of changes of volume after a similar given change of alveolar pressure in a subject with normal respiratory system resistance (---) and a resistance 3 times greater (\-\--) such as in COPD, assuming a constant compliance. Note the marked effect of resistance on the volume change, particularly when the available time is shortened.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease.](copd-1-381f2){#f2-copd-1-381}

![Iso-volume pressure-flow relationship. Schematic representation of the pressure-flow relationship in a healthy (normal) subject and a patient with COPD, showing the effect of the increased expiratory resistance upon the maximum expiratory flow and in both cases the independence of the maximum flow from the pleural pressure. Copyright © 1986. Modified with permission from [@b163-copd-1-381]. Lung mechanics in disease. In: Fishman AP (ed). Handbook of physiology, Section 3, Volume III, Part 2: The respiratory system. Bethesda MD: American Physiological Society, pp 659--92.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease.](copd-1-381f3){#f3-copd-1-381}

![Maximum and tidal flow-volume curves in subjects with and without flow limitation. In this figure it can be seen an schematic representation of the spontaneous flow-volume curves generated at tidal volume at rest (inner dotted line ····) and peak exercise (dashed line \-\-\--) compared with the maximum flow volume curve in a subject without flow limitation able to reduce its end-expiratory lung volume (Panel A) and a flow-limited COPD patient with dynamic hyperinflation (Panel B).\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; IC, inspiratory capacity.](copd-1-381f4){#f4-copd-1-381}

![Tidal volume encroachment by dynamic hyperinflation in COPD. In this figure the effects of respiratory rate and work rate on the end-inspiratory (EILV), end-expiratory lung volume (EELV), tidal volume (ie, EILV--EELV) and minute ventilation in subjects with severe COPD is displayed. While EILV increases with increasing respiratory rate from 20 to 30min^−1^ (lower left panel), so does EELV resulting in an almost constant (encroached) tidal volume. At respiratory rates higher than 30, though, EILV does not increase any more, however, EELV further increases resulting in a reduced tidal volume and even a drop in ventilation (left upper panel) at respiratory rates higher than 35min^−1^. In the right lower panel we can see how during progressive exercise tidal volume also decreases at high intensity due again to increase in EELV without parallel increase in EILV (Constructed with data from [@b165-copd-1-381]).\
**Abbreviation:** COPD, chronic obstructive pulmonary disease; EELV, end-expiratory lung volume; EILV, end-inspiratory lung volume; TLC, total lung capacity.](copd-1-381f5){#f5-copd-1-381}

###### 

Main clinical consequences of dynamic hyperinflation

  -----------------------------------------------------------
  Exercise limitation and dyspnea
  Hypoventilation during exercise
  Hypercarbic respiratory failure during exacerbations
  Hypercapnia during exercise
  Cardiac dysfunction during exercise
  Weaning failure
  Hypotension and barotraumas during mechanical ventilation
  Independent risk factor for survival in COPD subjects
  Reduced improvement with exercise training
  -----------------------------------------------------------

###### 

Summary of trials on BD measuring resting or dynamic hyperinflations an outcome

  Ref                     FEV~1~ (%)        "n"/design                                             Intervention                                                                       Duration   Resting PFT                        Resting hyperinflation           Exercise hyperinflation   Exercise dyspnea   Endurance time CLE          Comment
  ----------------------- ----------------- ------------------------------------------------------ ---------------------------------------------------------------------------------- ---------- ---------------------------------- -------------------------------- ------------------------- ------------------ --------------------------- ---------------------------------------------------------------------------------------------------------------
  **Single dose**                                                                                                                                                                                                                                                                                                                             
  ([@b15-copd-1-381])     40 (3)            13 cross-over against placebo                          200μg of salbutamol                                                                           Improvement in FEV~1~ and FVC                                       Improved                  Improved                                       
  ([@b121-copd-1-381])    52 (1)//78(1)\*   281 TLC\>133% and 676 TLC 113%--133%)//retrospective   200μg of salbutamol                                                                           \~30% improved FEV~1~              Reduced FRC RV//                                                                                          TLC was also reduced by BD. overall sensitivity may improve up to \~66% by measuring changes in lung volumes.
  ([@b169-copd-1-381])    52 (13)           16 with positive BD test//cross-over against placebo   50μg of salmeterol                                                                            Improvement in FEV~1~ and FVC      Reduced FRC                                                                                               lower dyspnea during resistive breathing
  ([@b19-copd-1-381])     47 (18)           20//11 with FL                                         400μg of salbutamol                                                                           No changes in FEV~1~               Improvement in IC only in FL                               Improved                                       Changes in dyspnea correlated with improvements in resting IC
  (Di Marco et al 2993)   52 (3)\*          20//cross-over against placebo                         200μg of salbutamol//12μg of formoterol//50μg of salmeterol//200μg of oxytropium              Improvement in FEV~1~              Increased IC                                                                                              Fomoterol better than salmeterol and than oxytropium//Those with decrease IC achieved a larger effect
  **Long-term**                                                                                                                                                                                                                                                                                                                               
  ([@b28-copd-1-381])     43 (12)           40/41//placebo controlled                              Tiotropium 18μg/d                                                                  4 weeks    Improvement in FEV~1~, FVC, SVC,   Increased IC and decreased FRC                                                                            
  ([@b128-copd-1-381])    44 (13)           96/91//placebo controlled                              Tiotropium 18μg/d                                                                  6 weeks    Improvement VC, but not FEV~1~,    Increased IC and decreased FRC   Improved                  Improved           105 (40)s (21%) \>than      
  ([@b102-copd-1-381])    43 (13)           131/117//placebo controlled                            Tiotropium 18μg/d                                                                  6 weeks    Improvement VC, but not FEV~1~,    Increased IC and decreased FRC   Improved                  Improved           171 (58) s\> than placebo   Effects seen at 2.5h still at 8h
  (O'Donnell2004c)        42 (3)\*          23//cross-over against placebo                         Salmeterol (50μg bid) added to the daily drug regimen.                             2 weeks    Increased FEV~1~, Improved         Increased IC                     Improved                  Improved                                       Increased In peak oxygen uptake and VT at 10w incremental test.
  (Man et al 2004)        32 (4)            16 "no reversible"//cross-over against placebo         Salmeterol (50μg bid) added to the daily drug regimen.                             2 weeks    No effect on FEV~1~, FVC, SVC,     Decreased RV/TLC                 Improved                  Improved           No improvement              Changes in dyspnea correlated with improvements DH and esophageal pressure

**Note:** Values are men with standard deviation within parenthesis; except \*SEM.

###### 

Subjects likely to benefit for lung volume surgery

  -------------------------------------------------------------------------
  Marked disability after rehabilitation (peak work rate \<40% predicted)
  Quit from smoking at least 6 month before
  Understanding of risks and benefits
  Heterogeneous enphysiema
  Marked hyperinflation
  DL~CO~ \<50% \>20% as percent of predicted
  FEV~1~ \< 35% \>20% as percent of predicted
  Normal ejection fraction
  -------------------------------------------------------------------------

**Abbreviations:** DL~CO~, diffusing capacity of the lung for carbon monoxide; FEV, forced expiratory volume in one second
